Loading people...
Anne Horgan is a Partner at Cambridge Innovation Capital in Cambridge, UK, where she leads early-stage life sciences investments for the £500 million venture capital fund. Before joining the firm, she served as a Partner at Advent France Biotechnology and a Senior Associate at Sofinnova Partners, building an extensive career in biotechnology company creation, due diligence, and deal sourcing. Her prior operational experience includes working as a Business Development Executive at Cancer Research Technology and a Senior Medicinal Chemist at Cambridge Biotechnology Ltd. She holds a doctorate in synthetic organic chemistry from the University of Bristol, completed her postdoctoral research at Yale University, and is listed as an inventor on eight distinct patent families. Horgan currently focuses on funding early-stage therapeutics and synthetic biology startups, managing active portfolio investments in emerging companies like Complement Therapeutics and Mosaic Therapeutics.
Anne Horgan serves as a distinguished Partner at Cambridge Innovation Capital (CIC), a premier venture capital firm dedicated to nurturing and scaling world-class innovation emerging from the Cambridge ecosystem. In her pivotal role, Anne is instrumental in identifying, evaluating, and investing in groundbreaking deep technology and life sciences companies, primarily spin-outs from the University of Cambridge. Her work directly contributes to CIC's mission of bridging the gap between pioneering academic research and successful commercial ventures.
Anne's investment focus aligns perfectly with Cambridge Innovation Capital's strategic pillars. She actively seeks out opportunities in areas such as biotechnology, pharmaceuticals, medical devices, artificial intelligence, advanced materials, sustainable technologies, and enterprise software. These investments typically involve early-stage companies leveraging proprietary intellectual property and disruptive science to address significant global challenges. Anne's keen eye for potential and deep understanding of complex scientific and technological landscapes enable her to back ventures with the highest promise for commercial success and societal impact.
Prior to her tenure at Cambridge Innovation Capital, Anne Horgan built a robust career foundation within the investment and technology sectors. Her background likely encompasses experience in venture capital, private equity, or strategic roles within innovative companies, providing her with a comprehensive perspective on company building and value creation. This diverse experience equips her with the ability to not only assess the scientific merit of a proposition but also to understand the market dynamics, operational challenges, and strategic pathways required for a startup to thrive. She is known for her hands-on approach, working closely with portfolio companies to provide strategic guidance, support management teams, and facilitate growth.
While specific individual investments for Anne Horgan are not always publicly detailed, her contributions are integral to Cambridge Innovation Capital's impressive portfolio. CIC has a strong track record of backing companies that have gone on to achieve significant milestones, including successful exits and further funding rounds, demonstrating the strength of the Cambridge innovation cluster. Anne plays a crucial role in identifying these future leaders, helping to transform cutting-edge research into market-leading products and services. Her commitment to fostering innovation ensures that Cambridge continues to be a global hub for scientific and technological advancement, driving economic growth and creating high-value jobs within the region and beyond. Investors and entrepreneurs seeking to understand the landscape of deep tech and life sciences funding in Cambridge will find Anne Horgan's expertise and Cambridge Innovation Capital's strategic approach highly relevant.
Anne Horgan is a Partner at Cambridge Innovation Capital, a venture capital firm that invests in deep technology and life sciences companies emerging from the Cambridge ecosystem. She plays a key role in identifying and supporting innovative spin-outs from the University of Cambridge.
Anne Horgan invests in deep technology and life sciences sectors, including biotechnology, pharmaceuticals, medical devices, AI, advanced materials, and sustainable technologies. Her focus is on early-stage companies with disruptive intellectual property from the Cambridge cluster.
Anne Horgan works as a Partner at Cambridge Innovation Capital, a leading venture capital firm based in Cambridge, UK, dedicated to commercializing innovation from the University of Cambridge and the wider region.
